minimum investment: $100.00
Teaching your dog's old immune system new tricks to fight cancer
CAVU Biotherapies is teaching your dog's old immune system new tricks to fight cancer by commercializing an innovative T-cell therapy called CAVU's Oncolytic LymphoTherapy (COLT). COLT is a cost-effective, personalized immunotherapy focused on the veterinary market. Not only can COLT provide significant value to our dogs and families through improved quality of life, but CAVU Biotherapies believes it may give veterinarian oncologists a new, more potent weapon in their arsenal.
Funding target: $68,000 – $1,000,000 by 11/25/2017
Regulation Crowdfunding: Equity (SAFE – Cap and Discount)
Minimum investment: $100
- Received approval from the federal and state regulatory boards for commercialization
- Submitted non-provisional patents covering our technology and trademarks protection in the U.S. and abroad
- Obtained pet insurance coverage for COLT
- Initiated an approved AKC-CHF supported pilot clinical trial with Texas A&M University
CAVU is an aeronautical term meaning “Ceiling and Visibility Unlimited”- that’s how we see the future of immunotherapy against cancer. We want to change the world by keeping pet families intact longer while becoming the global leader in immune-guided medicine. Our focus is not only on ending canine cancer, but to translate those results to treat horses and, one day, humans. By Year 5, we hope to have a global presence; provide services to over 25K U.S. dogs and enter into the human market.